OBJECTIVE: This study evaluates the relationship between sociodemographic/exposure factors and comorbidity, and their impact on lung cancer treatment and survival. STUDY AND DESIGN SETTING: Data for 1,155 patients were abstracted from the Josephine Ford Cancer Center Tumor Registry and medical records. Associations were analyzed by linear, logistic, and Cox regression. RESULTS: Approximately 88% of patients had > or = 1 of 56 comorbidities assessed. In multivariate analysis, comorbidity count was associated with older age, pack-years smoked, heavy alcohol use, lower socioeconomic status (SES), and female gender. Approximately 63% of patients had > or = 1 of 18 adverse prognostic comorbidities (AC), and significant independent predictors of AC were age, pack-years, African-American race/ethnicity, and gender. In multivariate analysis, comorbidity count and AC predicted nonreceipt of surgery in localized disease (OR(> or = 1 vs. 0 AC)=0.38, 95% 0.18, 0.81) and chemotherapy in advanced disease (OR > or = 1 vs. 0 AC)=0.72, 95% 0.51, 1.00). In adjusted analysis, comorbidity predicted survival in localized (hazard ratio (HR)(> or = 2 vs. 0 AC)=2.99, 95% CI 1.75, 5.10) and advanced lung cancer (HR(> or = 2 vs. 0 AC)=1.56, 95% CI 1.25, 1.94). CONCLUSION: Comorbidity has important deleterious effects on lung cancer outcomes and significant predictors of comorbidity included age, smoking, race/ethnicity, SES, alcohol, and gender.
OBJECTIVE: This study evaluates the relationship between sociodemographic/exposure factors and comorbidity, and their impact on lung cancer treatment and survival. STUDY AND DESIGN SETTING: Data for 1,155 patients were abstracted from the Josephine Ford Cancer Center Tumor Registry and medical records. Associations were analyzed by linear, logistic, and Cox regression. RESULTS: Approximately 88% of patients had > or = 1 of 56 comorbidities assessed. In multivariate analysis, comorbidity count was associated with older age, pack-years smoked, heavy alcohol use, lower socioeconomic status (SES), and female gender. Approximately 63% of patients had > or = 1 of 18 adverse prognostic comorbidities (AC), and significant independent predictors of AC were age, pack-years, African-American race/ethnicity, and gender. In multivariate analysis, comorbidity count and AC predicted nonreceipt of surgery in localized disease (OR(> or = 1 vs. 0 AC)=0.38, 95% 0.18, 0.81) and chemotherapy in advanced disease (OR > or = 1 vs. 0 AC)=0.72, 95% 0.51, 1.00). In adjusted analysis, comorbidity predicted survival in localized (hazard ratio (HR)(> or = 2 vs. 0 AC)=2.99, 95% CI 1.75, 5.10) and advanced lung cancer (HR(> or = 2 vs. 0 AC)=1.56, 95% CI 1.25, 1.94). CONCLUSION: Comorbidity has important deleterious effects on lung cancer outcomes and significant predictors of comorbidity included age, smoking, race/ethnicity, SES, alcohol, and gender.
Authors: Michael B Cook; Katherine A McGlynn; Susan S Devesa; Neal D Freedman; William F Anderson Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-07-12 Impact factor: 4.254
Authors: Melinda C Aldrich; Eric L Grogan; Heather M Munro; Lisa B Signorello; William J Blot Journal: J Thorac Oncol Date: 2013-10 Impact factor: 15.609
Authors: Ifeanyichukwu I Megwalu; Anna Vlahiotis; Mohamed Radwan; Jay F Piccirillo; Adam S Kibel Journal: Eur Urol Date: 2007-11-05 Impact factor: 20.096
Authors: Parisa Tehranifar; Alfred I Neugut; Jo C Phelan; Bruce G Link; Yuyan Liao; Manisha Desai; Mary Beth Terry Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-09-29 Impact factor: 4.254
Authors: Mary Putt; Judith A Long; Chantal Montagnet; Jeffrey H Silber; Virginia W Chang; J Sanford Schwartz; Craig Evan Pollack; Yu-Ning Wong; Katrina Armstrong Journal: Med Care Res Rev Date: 2009-04-08 Impact factor: 3.929